U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

Attorney Docket No.: CRNC.83071

Serial Number: 09/981,248

Applicant: Mark A. Hoffman and David P. McCallie, Jr.

Filing Date: October 16, 2001

Group: HECEIVEE

MAY 2 0 2

	·	U.S	S. PATENT DOCUMENTS	CUMENTS		
EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	NIEB 160 (2291)	
MM	5,833,599	11/10/98	Schrier, Robert W., et al.		04/09/96	
MM	6,081,786	06/27/00	Barry, David W., et al.		04/01/99	
nry,	6,067,524	05/23/00	Byerly, Baxter H., et al.		01/07/99	
Mit	5,758,095	05/26/98	Albaum, David, et al.		02/24/95	
:			 			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY OR PATENT OFFICE CLASS SUBCLASS YES NO

DTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

Lazarou, Jason, et al., "Incidence of Adverse Drug Reactions in Hospital Patients," JAMA, April 15, 1998, Vol. 279, No. 15.

Foubister, Vida, et al., "Expanded Genetic Testing Carries New Legal Risks," American Medical News, October 16, 2000, pp. 13-14.

Evans, William E., et al., "Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics," Science Magazine, Vol. 286, No. 5439, October 15, 1999, pp. 487-491.

Meyer, Urs A., et al., "Molecular Mechanisms of Genetic Polymorphisms of Drug Metabolism," Annu. Rev. Pharmacol, Toxicol. 1997, 37:269-96.

Sundberg, Magnus Ingelman- et al., "Polymorphic Human Cytochrome P450 Enzyes: An Opportunity for Individualized Drug Treatment, 20th Century Advances in Drug Development, J. Clin Pharmacol.2000; 40:930-938.

EXAMINER

DATE CONSIDERED

3 1/9/c²/

EXAMINER: Initial citation if refer nce was considered. Draw line through citation if not in conformanc to MPEP 609 and not consider d. Include copy of this form with next communication to applicant.

/	OIP		6)
	APR O	2003	Un ge r the

PTO/SB/08A (02-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sheet one

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of lone

Complete if Known				
Application Number	09/981,248			
Filing Date	October 16, 2001			
First Named Inventor	Mark A. Hoffman			
Art Unit	1431			
Examiner Name	MURAN			
Attorney Docket Number	CBNC 83071			

Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MUP!		^{US-} 2002/0049772	04-25-2002	Rienhoff, Jr., et al	=======================================
W		^{US-} 6,315,720	11/13/2001	Wililams, et al.	EC -
MAN		US- 2002/0012921	01/31/2002	Stanton, Jr.	
		US-			T T
		US-			重
		US-	7		33
		US-			9
		US-			8
-		US-			600/2900
		US-			5
		US-			1
		US-			
		ÚS-			,
		US-			
		US-	1		<u> </u>
		U\$-	 	 	1
		US-	 		
		US-	 	 	+
		US-			<u> </u>

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Tø
M		EP 1 211 627 A1	05/06/2002	Gut, Joseph		
			_			-

Examiner	711	M	Date	2/10/25/
Signature	1/1	1. 10-10-1	Considered	(3//9/0/

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.